On 23 February 2011, orphan designation (EU/3/10/833) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for doxorubicin hydrochloride (in heat-sensitive liposomes) for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to FGK Representative Service GmbH, Germany, in January 2019.
Doxorubicin hydrochloride (in heat-sensitive liposomes)
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;